Serotonin reuptake inhibitors and cardiovascular disease

Belcher, P.R., Drake-Holland, A.J. and Noble, M. (2005) Serotonin reuptake inhibitors and cardiovascular disease. Vascular Disease Prevention, 2(1), pp. 67-76.



Publisher's URL:


Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for endogenous depression. In addition to depleting the nerve terminals of serotonin they also lower blood platelet serotonin levels. Platelet aggregation is a major component of acute coronary syndromes, including sudden death, and also of limb ischaemia. Platelet-released serotonin causes constriction of diseased blood vessels. The recent literature has revealed a number of reports of association between the treatment of depression with SSRIs and reduced events caused by intra-arterial thrombosis. The effects of serotonin and serotonin depletion upon intracoronary thrombosis, diseased blood vessels, blood platelets and bleeding are discussed with recommendations for future research into the potential cardiovascular benefits of SSRIs and serotonin 5HT2A antagonists.

Item Type:Articles
Keywords:neurotransmitter; 5ht receptors; central nervous system; thrombosis
Glasgow Author(s) Enlighten ID:Belcher, PR
Authors: Belcher, P.R., Drake-Holland, A.J., and Noble, M.
Subjects:Q Science > QP Physiology
College/School:College of Medical Veterinary and Life Sciences
Journal Name:Vascular Disease Prevention
Publisher:Bentham Science Publishers
Copyright Holders:Copyright © 2005 Bentham Science Publishers
First Published:First published in Vascular disease prevention 2(1):67-76
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record